A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : KRAS / Kirsten rat sarcoma viral oncogene homolog

[Related PubMed/MEDLINE]
Total Number of Papers: 423
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   KRAS  (>> Co-occurring Abbreviation)
Long Form:   Kirsten rat sarcoma viral oncogene homolog
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Active Compound of Pharbitis Semen (Pharbitis nil Seeds) Suppressed KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during Cancer Progression. CRC, PN
2020 Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation. CRC, EGFR, mCRC
2020 Association of BMI and major molecular pathological markers of colorectal cancer in men and women. BRAF, CIMP, CRC, MSI
2020 Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma. ADC, EGFR, NGS, PD-L1
2020 Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers. PDAC
2020 BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. CRC, mCRC
2020 Circulating tumor DNA analysis in the era of precision oncology. ctDNA, EGFR
2020 Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA. BRAF, cfDNA, ctDNA, EGFR, MET, NGS, NRAS, NSCLC, PIK3CA, RM
2020 Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age. RAS, SA
10  2020 ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis. ERK, MAPK
11  2020 ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. EGFR, NSCLC, OS, p-Akt, p-ERK
12  2020 Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. ALK, EGFR, NSCLC, TKI
13  2020 Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma. HRAS, NRAS
14  2020 In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[18F]fluorothymidine PET/MRI. PCNA, PET, phh3, TIMP3, TK1, Vb, VEGF-A, WHO
15  2020 KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? CNS, GTP, NSCLC
16  2020 KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. CRCs, mCRC
17  2020 KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. EGFR, NGS, NSCLC
18  2020 KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). NSCLC
19  2020 Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. ANOVA, CRC, FDR
20  2020 Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. ALK, EGFR, NSCLC, PD-1, PD-L1, TILs
21  2020 Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. mCRC, RAS
22  2020 Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. CC, PPARgamma, SRC1
23  2020 Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms. AUC, CT, CTD, EGFR, FDR, LoG, MTV, NSCLC, PCR, PET, SGD, SM, SUV, VT
24  2020 Noninvasive KRAS mutation estimation in colorectal cancer using a deep learning method based on CT imaging. AUC, CRC, DL, ResNet, RFC, ROI
25  2020 Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma. BMP, ccRCC, DFS, EMT, GSEA, OS
26  2020 Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. ALK, DDR, EGFR, ICIs, NSCLC, PD-1, TP53
27  2020 Positive Correlation Between Somatic Mutations in RAS Gene and Colorectal Cancer in Telangana Population: Hospital-Based Study in a Cosmopolitan City. CRC, EGFR, NRAS
28  2020 Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. LADC, OS, PD-L1
29  2020 Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? PDAC
30  2020 Successful Multidisciplinary Treatment for Aggressive Primary Pulmonary Undifferentiated Pleomorphic Sarcoma. CT, MFH, UPS
31  2020 Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. NSCLC
32  2020 Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy. DSB
33  2020 The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis. EGFR, LARC, NCCN, nCRT, TME
34  2020 The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice. AKI, ATN, CDK4, LC3-II, NSCLC, PD-L1
35  2020 The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer. IFS, mRMR
36  2020 The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. CI, HR, OS, RFS
37  2020 Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer. ctDNA, EGFR, mCRC, NRAS, RAS-mt, RAS-WT
38  2020 [Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis]. ALK, CT, EGFR, ROS1
39  2020 [Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma]. ALK, EGFR, EGFR-TKI, HER2, NGS, STK11, TP53
40  2019 18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings. MTV, PD-L1, PFS, PSC, TLG
41  2019 A rare case of synchronous ovarian tumors: clinical case report and literature review. HP, NRAS
42  2019 Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale. ERK
43  2019 Association between methylation of DNA damage response-related genes and DNA damage in hepatocytes of rats following subchronic exposure to vinyl chloride. CDKN, MGMT, SYK, VC
44  2019 Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. BRAF, CIs, CRC, MSI, NSAIDs, ORs
45  2019 Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study. CRC, DFS, OS
46  2019 Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro. EGFR, siRNA
47  2019 Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma. ALK, DFS, EGFR, LAC, OS, RT, WT
48  2019 Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases. CRC, RAS
49  2019 Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. AFs, BRAF, EGFR, NGS
50  2019 CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. CT, FDG, PET, ROC
51  2019 Current Approaches in NSCLC Targeting K-RAS and EGFR. EGFR, NSCLC, TK
52  2019 Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis. CRC, DOR, FDG, LR, PET/CT, ROC
53  2019 Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations. DESCT, EGFR, NIC, NWC
54  2019 Exposure of the extracellular matrix and colonization of the ovary in metastasis of fallopian-tube-derived cancer. FTE, HGSOC, MOE, PTEN
55  2019 Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology. ADC, ALK, EGFR, FISH, IHC, LBC, ROS1
56  2019 HAO2 inhibits malignancy of clear cell renal cell carcinoma by promoting lipid catabolic process. ccRCC, DFS, EMT, GSEA, HAO2, OS
57  2019 Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer. ---
58  2019 MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin. miR-217
59  2019 MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma. miRNAs, SLC4A4
60  2019 Molecular association of functioning stroma with carcinoma cells in the ovary: A preliminary study. ARID1A, PIK3CA, PTEN
61  2019 Molecular Subtypes Are Frequently Discordant Between Lesions in Patients With Synchronous Colorectal Cancer: Molecular Analysis of 59 Patients. CRC, MLH1, TP53
62  2019 Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. CRC, OS, PFS
63  2019 Phenotypic Switching of Naive T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. MT, NSCLC
64  2019 Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. ERK
65  2019 Potential function of microRNAs in thoracic aortic aneurysm and thoracic aortic dissection pathogenesis. MAPK, TAA, TAD, TAGLN
66  2019 Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. NSCLC, PD-L1
67  2019 Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study. ALK, DESCT, EGFR, IC, WC
68  2019 RAS mutation: site of disease and recurrence pattern in colorectal cancer. CRC, LiM, OS, RFS
69  2019 Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. CMSs, CRC
70  2019 Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas. CDCP1, CRCs, CSCs, PPP, ROS, Sirt5, TPI
71  2019 The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. AUC, EGFR, miRNAs, NSCLC
72  2019 The Role of KRAS in Endometrial Cancer: A Mini-Review. EC, MAPK
73  2019 Transistor-like Ultra-pH-Sensitive Polymeric Nanoparticles. UPS
74  2019 Use of cell free DNA as a prognostic biomarker in non-small cell lung cancer patients with bone metastasis. NSCLC
75  2018 Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma. ALK, BRAF, EGFR, GGN, GGO, HER2, PD-1, PD-L1, PIK3CA
76  2018 Afatinib restrains K-RAS-driven lung tumorigenesis. EGFR, NSCLC, TKIs
77  2018 Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma. EGFR, VEGF, VEGFR
78  2018 beta-Catenin maintains lung epithelial progenitors after lung specification. FGF, GI, NKX2-1, SOX2, SOX9, TRAP
79  2018 Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation. OS, PFS, TMB
80  2018 Clinicopathological Characteristics and KRAS Mutation Status of Endometrial Mucinous Metaplasia and Carcinoma. ---
81  2018 Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. CI, CNS, ECOG PS, EGFR, NSCLC, OR, ORR, OS, PD-L1, PD1, PFS, RCTs, TRAEs
82  2018 Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas. CI, CT, EGFR, OR
83  2018 Cordyceps militaris Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway. ERK
84  2018 Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer? ROC
85  2018 Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid. CSF, EGFR, HER2, PCR
86  2018 Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia. Cbl, CEBPA, JAK2, NPM1, TET2
87  2018 Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. EGFR, PPMA
88  2018 Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series. CRC, CRLM
89  2018 Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort. mCRC, OS
90  2018 EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients. EGFR, PIK3CA, PTEN, SCLC
91  2018 Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. ALK, EGFR, NSCLC, ROS1, SCLC
92  2018 Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. EGFR, IMA, PD-L1, TP53
93  2018 Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. ALK, EGFR, EML4, NSCLC, PD-L1
94  2018 Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer. APC, DDR2, EBC, EGFR, ERBB4, FBXW7, FGFR1, FGFR3, MET, NGS, PIK3CA, PTEN, RET, SMAD4, STK11, TP53
95  2018 Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS. IPMN
96  2018 KRAS-Mutant non-small cell lung cancer: From biology to therapy. NSCLC
97  2018 Liver dual arterial blood supply maintains liver regeneration: Analysis of signaling pathways in rats. LDABS, LRR, Mapk10, PCR, PH, RB1
98  2018 Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. EGFR, NSCLC, TKIs
99  2018 Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma. Bcl-2, miR-31
100  2018 MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance. CSC, GBM, STAT3